Intergenerational Hemophilia A Program to Understand Factor VIII Immune Responses
A Severe Hemophilia A Intergenerational Cohort Research Program for the Study of Factor VIII Immunogenicity
This program follows mothers who carry hemophilia A and their babies with severe hemophilia to learn how immune reactions to factor VIII develop in early life.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11376434 on NIH RePORTER |
What this research studies
If you join, you and your baby would be followed from pregnancy through at least the first two years of life as part of a mother-baby paired cohort. The program will collect medical information and biological samples like blood to look for genetic markers and immune signals linked to development of inhibitors against factor VIII. Samples and de-identified data will be stored in a shared portal and biorepository so other researchers can use them to study why immune responses happen. The project coordinates protocols across clinical centers to focus on antenatal, perinatal, neonatal, and event-driven pediatric research.
Who could benefit from this research
Good fit: Ideal candidates are pregnant women who are known genetic carriers of hemophilia A and their babies who are diagnosed with or expected to have severe hemophilia A, especially during pregnancy and the first two years of life.
Not a fit: People without a hemophilia A carrier pregnancy or babies/children who do not have severe hemophilia A (for example those with mild or moderate disease or unrelated conditions) are unlikely to receive direct benefit from participating.
Why it matters
Potential benefit: If successful, this work could identify early markers or causes of factor VIII inhibitors and help guide ways to prevent or reduce harmful immune reactions in children with severe hemophilia A.
How similar studies have performed: Previous studies have identified some genetic and immune risk factors for factor VIII inhibitors, but this intergenerational, longitudinal mother-to-infant cohort approach is relatively new.
Where this research is happening
Seattle, United States
- University of Washington — Seattle, United States (Active)
Researchers
- Principal investigator: Johnsen, Jill Marie — University of Washington
- Study coordinator: Johnsen, Jill Marie
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.